Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could low muscle mass predict nerve pain from chemo?

NCT ID NCT06996548

Knowledge-focused Sponsor: Gazi University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 120 women with early-stage breast cancer to see if having low muscle mass (sarcopenia) before treatment raises the risk of nerve damage from the chemotherapy drug paclitaxel. Researchers measured muscle mass on CT scans and checked for nerve symptoms using questionnaires and nerve tests. The goal was to find out if muscle loss can help predict who might get nerve problems from chemo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

120 people

The number who actually took part.

Started

Nov 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consisted of adult female patients diagnosed with early-stage breast cancer and treated with neoadjuvant or adjuvant paclitaxel-based chemotherapy regimens at three oncology centers in Turkey. Patients were enrolled consecutively if they met the inclusion criteria and provided informed consent. Data were collected prospectively, including pre-treatment CT scans for muscle mass analysis and neuropathy assessments.

Ages

18 to 80 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed early-stage breast cancer * Planned to receive neoadjuvant or adjuvant paclitaxel-based chemotherapy * Patients receiving paclitaxel-carboplatin or paclitaxel-trastuzumab-pertuzumab regimens are also eligible * Provided written informed consent Exclusion Criteria: * Age \< 18 years * No pathological diagnosis of breast cancer * Refusal to participate in the study * Male patients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm chemotherapy-induced neuropathy Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast carcinoma Paclitaxel induced neuropathy Sarcopenia

Contacts and locations

Locations

  • Ankara Etlik City Hospital

    Ankara, Yenimahalle, 06170, Turkey (Türkiye)

  • Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

    Ankara, Yenimahalle, 06200, Turkey (Türkiye)

  • Gazi University

    Ankara, Yenimahalle, 06560, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.